Patents Assigned to Sunesis Pharmaceuticals, Inc.
  • Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
    Patent number: 11174243
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: November 16, 2021
    Assignees: Sunesis Pharmaceuticals, Inc., Biogen MA Inc.
    Inventors: J. Michael Macphee, Linda L. Neuman
  • Pyrimidinyl tyrosine kinase inhibitors
    Patent number: 10618887
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: April 14, 2020
    Assignees: Sunesis Pharmaceuticals, Inc., Biogen MA Inc.
    Inventors: Brian T. Hopkins, Timothy R. Chan, Tracy J. Jenkins, Patrick Conlon, Xiongwei Cai, Michael Humora, Xianglin Shi, Ross A. Miller, Andrew Thompson
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10577374
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: March 3, 2020
    Assignees: Sunesis Pharmaceuticals, Inc., Biogen MA Inc.
    Inventors: Minna Bui, Patrick Conlon, Julio H. Cuervo, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Tracy J. Jenkins, Gnanasambandam Kumaravel, Alexey A. Lugovskoy, Doug Marcotte, Noel Powell, Daniel Scott, Laura Silvian, Art Taveras, Deping Wang, Min Zhong
  • Methods of chemotype evolution
    Patent number: 10107798
    Abstract: Herein is described a method to rapidly screen a large chemical space for a compound that binds to a target protein through an iterative fragment assembly approach that can be performed at low reagent cost and without requiring purification of the assembled product. The method employs a library of test ligands each of which comprise a ‘bait’ molecule, which is known from prior art or prior screening to have some intrinsic affinity for the target protein, and a test moiety.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: October 23, 2018
    Assignee: SUNESIS PHARMACEUTICALS, INC.
    Inventors: Stig Hansen, Daniel Erlanson, Mark Cancilla
  • CHEMICAL SYNTHESIS
    Publication number: 20180238863
    Abstract: Herein are described methods of chemical synthesis.
    Type: Application
    Filed: January 12, 2018
    Publication date: August 23, 2018
    Applicant: Sunesis Pharmaceuticals, Inc.
    Inventors: Stig Hansen, Daniel Erlanson, Mark Cancilla
  • Heterocyclic compounds useful as PDK1 inhibitors
    Patent number: 10030016
    Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: July 24, 2018
    Assignees: Sunesis Pharmaceuticals, Inc., Millenium Pharmaceuticals, Inc.
    Inventors: Joseph Arndt, Timothy Chan, Kevin Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Daniel Scott, Lihong Sun, Jermaine Thomas, Kurt van Vloten, Deping Wang, Lei Zhang, Daniel Erlanson
  • SNS-595 and methods of using the same
    Patent number: 9980949
    Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: May 29, 2018
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Michelle Arkin, Jennifer Hyde, Duncan Walker, Jasmin Wright
  • Stable SNS-595 compositions and methods of preparation
    Patent number: 9969730
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 15, 2018
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Pyrimidinyl tyrosine kinase inhibitors
    Patent number: 9944622
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 17, 2018
    Assignees: Biogen MA Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Brian T. Hopkins, Timothy R. Chan, Tracy J. Jenkins, Patrick Conlon, Xiongwei Cai, Michael Humora, Xianglin Shi, Ross A. Miller, Andrew Thompson
  • Substituted pyrimidines for inhibiting Raf kinase activity
    Patent number: 9920048
    Abstract: The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein Rx, Ry, R1, L1, L2, Cy1, and Cy2 are as defined as set forth in the specification.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 20, 2018
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong Chen, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Methods of treatment using pyridinonyl PDK1 inhibitors
    Patent number: 9873693
    Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: January 23, 2018
    Assignees: Sunesis Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth Egnard Lind, Kathy Cao, Edward Yin-shiang Lin, Thinh Ba Nguyen, Bradley T. Tangonan, Daniel A. Erlanson, Kevin Guckian, Robert Lowell Simmons, Wen-cherng Lee, Lihong Sun, Stig Hansen, Nuzhat Pathan, Lei Zhang
  • Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
    Patent number: 9839630
    Abstract: Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: December 12, 2017
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Tamilarasan Subramani, Mohamed Rahuman, Ramar Subbiah
  • Bruton's tyrosine kinase inhibitors
    Patent number: 9790229
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: October 17, 2017
    Assignees: Sunesis Pharmaceuticals, Inc., Biogen MA Inc.
    Inventors: Minna Bui, Patrick Conlon, Julio H. Cuervo, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Tracy J. Jenkins, Gnanasambandam Kumaravel, Alexey A. Lugovskoy, Doug Marcotte, Noel Powell, Daniel Scott, Laura Silvian, Art Taveras, Deping Wang, Min Zhong
  • SNS-595 and methods of using the same
    Patent number: 9757363
    Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: September 12, 2017
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Daniel C. Adelman, Jeffrey A. Silverman
  • Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
    Patent number: 9724338
    Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: August 8, 2017
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventor: Glenn Michelson
  • Compounds and compositions for treatment of cancer
    Patent number: 9676774
    Abstract: Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: June 13, 2017
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Daniel C. Adelman, Marc J. Evanchik, Anantha Sudhakar, Jeffrey William Jacobs, Jeffrey A. Silverman
  • Compounds Useful as Raf Kinase Inhibitors
    Publication number: 20170158686
    Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Application
    Filed: December 15, 2016
    Publication date: June 8, 2017
    Applicants: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong CHEN, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors
    Patent number: 9556177
    Abstract: The present disclosure provides compounds having Formula II-vi-a: wherein Cy1, Cy2, and A? are defined as set forth in the specification. These compounds are synthetic intermediates used to prepare inhibitors of Raf protein kinase.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: January 31, 2017
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong Chen, Benjamin Lane, Hairuo Peng
  • Heterocyclic compounds useful as PDK1 inhibitors
    Patent number: 9546165
    Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: January 17, 2017
    Assignees: Sunesis Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc.
    Inventors: Joseph Arndt, Timothy Chan, Kevin Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Daniel Scott, Lihong Sun, Jermaine Thomas, Kurt van Vloten, Deping Wang, Lei Zhang, Daniel Erlanson
  • Stable SNS-595 compositions and methods of preparation
    Patent number: 9469635
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: October 18, 2016
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng